[Procognitive effects of fluvoxamine: preliminary data].

Aim: To identify and investigate procognitive effects of fluvoxamine.

Material And Methods: A prospective non-comparative trial of fluvoxamine was carried out in 50 patients in the remission phase of recurrent depressive disorder. To assess the efficacy of therapy, the Stroop color and word test, the Revised version of Addenbrooke's Cognitive Examination, the Frontal Assessment Battery, the Hamilton Depression Scale and the Social Adaptation Self-Evaluation Scale were used.

[Cognitive impairment in depression and potential applications of antidepressants with procognitive effects].

The characteristics of cognitive impairment in depression are reviewed. Data of literature indicate that cognitive impairment may serve as a predictor of depression recurrence and poor prognosis of antidepressant therapy. In this view, we consider the importance of assessment of cognitive impairment and differential use of medications with precognitive effect (bupropion, vorteoxetine and some SSRI antidepressants as well as fluvoxamine, which is a potent agonist of the sigma-1-receptor).

[Pantogam in the treatment of patients with organic brain lesions of different genesis].

We studied 35 patients with organic brain lesions caused by secondary brain harmful factors (group 1) and 33 patients with organic brain diseases of vascular genesis (group 2). Mean age of patients was 45.5±2.